Company intelligence / Profile preview

Theravir

Baltimore, Maryland, United States

Ownership: Private
Development stage: Other

Overview

Theravir is a biotechnology company focused on the development of novel antiviral therapies for life-threatening viral infections, including HIV and COVID-19. The company's lead research efforts center on next-generation protease inhibitors designed to overcome drug resistance and improve safety profiles compared to existing treatments. Founded by prominent virologists, Theravir leverages deep expertise in viral replication and structural biology to design small molecule candidates. The company is currently advancing its pipeline through pre-clinical stages with the goal of addressing significant unmet needs in global infectious disease management.

Therapeutic areas: Infectious Diseases
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Theravir.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Theravir.

Explore the full profile